Adjuvant Treatment of Resected Pancreatic Adenocarcinoma

Introduction to m-FOLFIRINOX and Gemcitabine-Capecitabine

• The National Comprehensive Cancer Network (NCCN) recommends both m-FOLFIRINOX and gemcitabine-capecitabine as Category 1 "preferred" regimens in the adjuvant setting for resected pancreatic adenocarcinoma, with m-FOLFIRINOX demonstrating superior survival outcomes (median OS 54.4 vs 35.0 months compared to gemcitabine alone) but reserved for patients with excellent performance status (ECOG 0-1) 1, 2, 3

Efficacy Data

• The median disease-free survival for m-FOLFIRINOX is 21.6 months (95% CI, 17.7–27.6) vs 12.8 months with gemcitabine alone 1, 4
• The median overall survival for m-FOLFIRINOX is 54.4 months vs 35.0 months with gemcitabine alone 1, 4, 5
• The median overall survival for gemcitabine-capecitabine is 28.0 months vs 25.5 months with gemcitabine alone (HR 0.82; 95% CI, 0.68–0.98; P=0.032) 2, 5, 6

Toxicity Profiles

• Grade 3-4 adverse events occurred in 75.9% of patients receiving m-FOLFIRINOX 1, 4, 7
• Grade 3-4 adverse events occurred in 52.9% of patients receiving gemcitabine-capecitabine 1, 4
• Specific grade 3-4 toxicities for m-FOLFIRINOX include neutropenia (46%), febrile neutropenia (5%), fatigue (24%), vomiting (15%), diarrhea (13%), and peripheral neuropathy (9%) 8

Patient Selection

• The NCCN recommends choosing m-FOLFIRINOX for patients with ECOG performance status 0-1, age typically <70 years, no major comorbidities, adequate organ function, and no significant baseline neuropathy 1, 3, 7, 8
• The NCCN recommends choosing gemcitabine-capecitabine for patients with ECOG performance status 2 or borderline ECOG 1, older patients, or those with significant comorbidities 1, 3, 6

Guideline Consensus Position

• Both regimens hold equal Category 1 "preferred" status per NCCN guidelines, with selection based on patient fitness rather than one being universally superior 1, 2, 3, 7
• The ESMO guidelines similarly recognize m-FOLFIRINOX as the reference standard for fit patients, with gemcitabine-capecitabine reserved for those not eligible for the more intensive regimen 6